ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1223

Enhancement of Proinflammatory Cytokine Production By Uric Acid in Human Cells Via Down Regulation of IL-1Ra

Tania Crisan1, Maartje Cleophas2, Heidi Lemmers3, Helga Toenhake-Dijkstra1, Mihai Netea1, Tim Jansen4 and Leo Joosten1, 1Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, 2Internal Medicine, Radboud Unversity Medical Center, Nijmegen, Netherlands, 3Internal Medicine, Radboud Univeristy Medical Center, Nijmegen, Netherlands, 4Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: gout, inflammation and uric acid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Metabolic and Crystal Arthropathies: Mechanisms of Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose

Gout is an autoinflammatory disease characterized by the deposition of monosodium urate (MSU) crystals in the joints of hyperuricaemic patients and subsequent attacks of severe gouty arthritis. Major lines of research investigating the proinflammatory effects of uric acid have been mainly focusing on MSU crystal-induced processes that come into role once uric acid reaches supersaturation. However, some indications exist that uric acid can directly have pro-inflammatory effects.  In this study we investigate the effects of high uric acid exposure on the cytokine production of primary human immune cells upon stimulation with MSU crystals and synergizing agents.

Methods

Peripheral blood mononuclear cells (PBMCs) were harvested from gout patients and healthy volunteers. Cells were pre-treated with uric acid, allantoin or left untreated for 24h and then subjected to 24h stimulation with TLR2 or TLR4 ligands in the presence or absence of MSU. Cytokine production was assessed using specific sandwich ELISA kits. mRNA levels were measured using quantitative real-time PCR.

Results

MSU crystals stimulation alone did not induce detectable levels of IL-1β or IL-6 neither in patients nor in controls, however, synergy was present between MSU and Pam3Cys or LPS. Of high importance, higher levels of IL-1β and IL-6 were seen in patients compared to controls. An enhanced pro-inflammatory cytokine production was also observed when cells were specifically pretreated with uric acid, together with a significant down regulation of IL-1Ra but not IL-10. This observation correlated with mRNA levels for these cytokines observed in uric acid pre-treated cells.

Conclusion

In this study we propose a mechanism in which high uric acid concentrations might influence inflammatory responses by facilitating IL-1β production in immune cells. We show that a mechanism for the amplification of IL-1β consists in downregulation of IL-1Ra production that has the role of counterbalancing IL-1β auto-induction loop. As a consequence, patients having hyperuricaemia could be at risk of exhibiting increased vulnerability upon encounter of acute inflammatory stimuli and this might induce enhanced states of inflammation.


Disclosure:

T. Crisan,
None;

M. Cleophas,
None;

H. Lemmers,
None;

H. Toenhake-Dijkstra,
None;

M. Netea,
None;

T. Jansen,

Abbvie,

2,

UCB,

2,

Abbvie,

5,

AstraZeneca,

5,

UMS,

5,

Janssen Pharmaceutica Product, L.P.,

5,

Menarini,

5,

Novartis Pharmaceutical Corporation,

5,

Pfizer Inc,

5,

Roche Pharmaceuticals,

5,

Abbvie,

8;

L. Joosten,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/enhancement-of-proinflammatory-cytokine-production-by-uric-acid-in-human-cells-via-down-regulation-of-il-1ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology